{"id":"W3201746679","doi":"10.1016/j.annonc.2021.08.112","title":"716TiP IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Atezolizumab; Adjuvant; Placebo; Oncology; Internal medicine; Bladder cancer; Urology; Immunotherapy; Cancer; Pathology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001411226,0.001894251,0.003028002,0.0004497069,0.0003437261,0.001240388,0.00098179,0.002009166,0.009576336],"category_scores_gemma":[0.001095196,0.0008799738,0.002079339,0.0004549745,0.001261411,0.0009530045,0.0005226446,0.00386092,0.001771121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005075531,"about_ca_system_score_gemma":0.001190211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009624643,"about_ca_topic_score_gemma":0.00223247,"domain_scores_codex":[0.9995525,0.0002333042,0.00002004179,0.00008044638,0.00002303731,0.00009063575],"domain_scores_gemma":[0.9994591,0.0001334966,0.00008854723,0.00004324185,0.00003535111,0.0002402698],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9723332,0.005421431,0.0003932723,0.0005856698,0.0006871986,0.00002311494,0.00003559671,0.0002962863,0.004814945,0.00009315214,0.0008135393,0.01450252],"study_design_scores_gemma":[0.9410805,0.05652743,0.001053504,0.00001745208,0.0003000867,0.00001923655,0.00001322597,0.0001877685,0.0003055822,0.00005068929,0.0004330869,0.00001146333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807567,0.00485421,0.001470138,0.0009911521,0.0008594842,0.004134812,0.002678272,0.0003998993,0.003855447],"genre_scores_gemma":[0.974369,0.004080425,0.002376195,0.002104409,0.0005944145,0.004306666,0.003500578,0.00009508078,0.008573216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009576336,"threshold_uncertainty_score":0.03203607,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04872930099097921,"score_gpt":0.3650103161265907,"score_spread":0.3162810151356115,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}